Is PROCEPT BioRobotics Corporation (PRCT) A Good Stock To Buy Now?

Master Video/Shutterstock.com

Procept BioRobotics (PRCT) is simply a high-growth surgical robotics institution with accelerated gross scaling and expanding gross margins, with revenues having quadrupled since 2022, indicating early-stage economies of standard akin to starring medtech robotics peers. The company's existent operating basal is benchmarked against Intuitive Surgical (ISRG), wherever ISRG successful mid-2006 had crossed astir a akin ~$300 cardinal gross threshold, comparable gross margins, and a importantly larger superior base, yet traded done a volatile 9–18x income aggregate range.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

By contrast, PRCT presently trades astatine astir 4.5x income contempt increasing faster astatine a akin developmental stage, creating a notable valuation spread comparative to humanities ISRG execution. If PRCT continues to replicate ISRG's trajectory, aggregate enlargement and gross maturation could thrust important equity upside, with imaginable ~150% appreciation implicit a three-year skyline driven by gross compounding and re-rating. Near-term sentiment is mixed owed to absorption guiding gross somewhat beneath expectations, though inactive reflecting ~30% year-over-year growth, which introduces short-term skepticism.

However, guardant visibility improves importantly with 2027 gross guidance pointing to a step-change acceleration that remains underappreciated by analysts, mounting up a imaginable upside astonishment cycle. Even successful a much blimpish script wherever expert expectations beryllium accurate, the concern is inactive expected to prolong ~25% yearly gross growth, limiting downside hazard fixed the already compressed valuation multiple. With constricted grounds of structural de-rating catalysts absent execution failure, PRCT presents a skewed risk-reward illustration wherever continued robotic country adoption, scalable margins, and peer-multiple convergence could collectively re-rate the banal meaningfully higher implicit time.

Previously, we covered a bullish thesis connected Intuitive Surgical, Inc. (ISRG) by Kontra Investment Xchange successful December 2024, which highlighted robotic country leadership, da Vinci strategy growth, and expanding process volumes. ISRG's banal terms has depreciated by astir 25.79% since our coverage. mrmrmrj shares a akin presumption but emphasizes valuation spread versus PROCEPT BioRobotics and faster early-stage growth, but disagree successful maturity and valuation framing.